Origin Therapeutics, an investment company focused on psychedelic therapies, has added Canadian biotech Clairvoyant to its portfolio.
Clairvoyant is developing psychedelic drug therapy focused on addiction and is targeting the clinical validation of psilocybin in the EU, the UK, and Canada. The company is currently proceeding with a Phase II clinical trial in Canada for the clinical validation of psilocybin for the treatment of alcohol use disorder (AUD). The trial will evaluate the safety and efficacy of a 25mg synthetic psilocybin capsule versus placebo, delivered in conjunction with Motivational Enhancement Therapy (MET).
Fifteen clinical trial sites are planned for Clairvoyant’s Phase 2 clinical trial. The first site in Canada was initiated in June. Regulatory submissions have also been submitted in the EU for Clairvoyant to initiate clinical trial sites.
Official comments
“Psychedelic medicine delivered in conjunction with therapy has been demonstrated by compelling clinical research to have potentially profound positive effects on those suffering from substance use disorders,” said Alexander Somjen, CEO of Origin Therapeutics. “Clairvoyant has a unique speed-to-market strategy for psilocybin therapy and an experienced drug development team. We believe that Clairvoyant makes an excellent addition to our portfolio.”
“We are in the midst of a substance abuse crisis, and psychedelic therapies have the potential to provide patients with a new therapeutic intervention rather than having those patients be limited to options that often do not work or that may have unpleasant side effects,” said Damian Kettlewell, CEO of Clairvoyant. “We are pleased to be working with the Origin Therapeutics team to drive our vision forward.”
